Richard Miskimins , 1 Shibani Pati, 2 and Martin Schreiber 3 As with all areas of medicine, high-quality clinical research is essential to improving the care of trauma patients. This research is crucial in developing evidencebased treatments that decrease cost, decrease morbidity, and improve mortality. Trauma continues to extract a significant toll on society and is the single largest cause of years of life lost in the United States. The need to conduct high-quality clinical research in trauma is not disputed. However, significant challenges and barriers unique to the field of trauma make performing this research more difficult. It is critical to be aware of these challenges and barriers to performing clinical research involving trauma patients so these challenges can be accounted for and solutions implemented to minimize their impact on research. This review will focus on the barriers and challenges that are encountered while performing clinical research in trauma.
T raumatic injury is the leading cause of death for individuals 46 years old and younger and is the single largest cause of years of life lost in the United States. 1 In 2016, there were 231,991 fatal injuries and more than 32 million emergency department visits related to injuries. The economic cost associated with all fatal and non-fatal injuries in 2013 was 671 billion dollars. 2 In a review of morality data from 2000 to 2010 Rhee, et al. found a 22.8% increase in death from traumatic injury while during that same time there was a decrease in the rate of death from cancer and heart disease. 1 Injury has rapidly advanced from the 5th leading cause of death in all age groups in 2012 to the 3rd leading cause of death behind only heart disease and cancer. 3 This steady increase in mortality is reinforcing the need to increase trauma research.
Compared to the magnitude of the disease process, trauma is the most poorly funded public health problem in the United States. 4 Improving outcomes requires clinical research that enhances diagnostic accuracy, decreases costs, decreases morbidity, and improves mortality. The need to conduct high-quality clinical research is not disputed, however, there are barriers and challenges unique to the discipline that make performing clinical research more difficult. To overcome these obstacles they must be identified, and then solutions must be developed and incorporated into the conception, design, and execution of trials. This review will focus on barriers and challenges to performing clinical research in trauma.
CONSENT Obtaining consent
Informed consent is a critical protection and an essential part of human subject's research, and yet in prospective studies involving traumatic injuries it can be a barrier to conducting quality research studies. It has been shown that rapid diagnosis and early treatment improves trauma patient outcomes. 5 The time sensitive nature and severity of injury makes obtaining informed consent challenging for severely injured trauma patients. The common rule which governs human research studies states that "An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence." 6 Meeting these requirements for a patient that has sustained a severe traumatic brain injury, is facing life-threatening hemorrhage, is intoxicated, or has a diminished level of consciousness is not possible. In these situations, the patient's representative who could legally provide consent on their behalf is rarely immediately available after injury. The challenge of obtaining consent was demonstrated by Dutton et al. 7 in a prospective observational study involving 1,734 trauma admissions. They evaluated the patient's ability to provide consent to a hypothetical research study within 1 hour of admission or to have the patient's legal representative consent within 3 hours of arrival at the trauma center. They found 43% of patients at presentation were not approachable for consent secondary to being intubated, intoxicated, having a language barrier, or having an altered level of conscious. More than 50% did not have a legally authorized representative available within 3 hours of arriving at the trauma center. In the 57% who were approachable for consent only one third were deemed able to provide consent, with the other two thirds impaired or potentially impaired. Those who could consent for themselves had lower injury severity scores and those with a legally authorized representative available in less than 3 hours were less injured, more likely to be minors, female, and involved in blunt trauma. They concluded the majority of severely injured trauma patients would be excluded from the hypothetical trial and the trial would not be representative of the true population of trauma patients. The hypothetical situation explored by Dutton was seen in the CONTROL trial of factor VIIa for acute hemorrhagic shock. To expedite worldwide enrollment in the trial, study designers elected to proceed without an exception to informed consent in the United States and rely on consent from the patient or their legally authorized representative. 8 Of all patients eligible for enrollment in the United States, only 17% were enrolled and 26% of these patients consented for themselves compared with only 7% who consented for themselves internationally. Those in the United States who were eligible but unable to consent had an average of 14 units of packed red blood cells transfused while those who consented averaged 8.2 units. 9 By not seeking an exception to informed consent and relying on the legally authorized representative, the trial failed to enroll the target patient population.
Understanding consent
When a legal representative is available in a timely manner to provide informed consent, barriers still exist. The representative must absorb and interpret a significant amount of complex information such as the extent of injuries, the required interventions with the associated risks, and the overall prognosis. Since the treatment of the severely injured patient is time critical they must absorb and process all the information presented in a short period of time and under the emotionally distressing setting of the recent traumatic event. They must then apply what they have processed to the risks and benefits of the trial for which they are consenting. With these time constraints and the emotional distress of the event, most would agree there is insufficient time to adequately assess the risks and benefits of the study, ask questions, and reach an informed decision on study participation. 10 This inability to truly make an informed decision and consent to participate in a study in an emergent situation was emphasized by Mann et al. 11 where it was found that only "between 1% and 25% of patients leave the emergency department fully understanding the study in which they have been enrolled." The challenge of fully understanding the risks and benefits of a consent for a clinical trial was described by Joffe et al. who found 63% of patients enrolled in a clinical trial for cancer did not recognize at least one of the following: 1) the treatment was nonstandard, 2) there was potential for increased risk from participating, and 3) the nature of the treatment was unproven. 12 Although not a trial in trauma, this emphasizes the complex nature of the consent process in an elective setting, where treatment is not immediately needed. In this elective setting the majority of individuals still did not comprehend a critical element of the consent process. Providing informed consent in a way that is simple and the patient or legally authorized representative can comprehend the potential benefits and risks in the emotionally charged situation of a severe traumatic injury is a challenge that should be the focus of further research.
Exception from informed consent
As discussed, there are challenges to the consent process in trauma. To allow for research to be conducted in emergent situations, the FDA developed the common rule which outlined explicit situations in which emergency research can be conducted in humans under an exception to informed consent and must follow the guidelines of 21CFR50.24.
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These guidelines state "the research holds out the prospect of direct benefit to the individual." There is no definition of what a "direct benefit" to the patient is, and patients in both the intervention group and control group must potentially benefit. The regulation also states there must be no other feasible way to perform the research and no feasible way to identify individuals likely to become eligible for participation. Consultation and public disclosure to representatives in the communities in which the clinical investigation will be performed is required and a data monitoring committee must provide oversight. This provision for emergency research allowed by the common rule however is difficult to implement and not commonly used.
14 These challenges range from the cost of community consultation, the varying level of comfort of local institutional review boards and even inadequate standardization with different interpretations across multiple federal institutions. 5 
STUDY DESIGN Variability of patients
Trauma affects patients of all races, age, sex, and comorbidities. It includes unhelmeted children involved in bicycle accidents, young men in urban trauma centers who sustain penetrating injuries that result in severe hemorrhage, and nursing home patients with atrial fibrillation, on anti-coagulation who develop subdural hemorrhage after a ground-level fall. The variability in age, sex, mechanism of injury, functional status, and medical comorbidities all contribute to the final outcome among trauma patients. Performing clinical trials in such a heterogeneous group is inherently complex and more difficult to study when compared to a medication to treat middle-aged adults with essential hypertension. 15 
Difference in injury
Even in patients with similar baseline characteristics and comorbidities, injuries are heterogeneous with respect to mechanism, severity, and outcome. The application of an outside force can result in a single injury, multiple injuries to the same organ, or multiple injuries to multiple organ systems. Each injury differs in its potential for harm, timing of management, and effect on comorbid conditions. The healthy 20-year-old with a splenic injury and severe traumatic brain injury is different than a healthy 20-year-old with a splenic injury and multiple long bone fractures. Creating a study that randomizes a single traumatic injury to an intervention among patients with similar comorbidities and identical injuries both anatomically and physiologically is inherently challenging simply because of the heterogeneity of trauma populations. 8 Adequately powering studies Thirty-day mortality has been the standard outcome in clinical trials performed under exception from informed consent. This outcome requires very large populations to determine if early interventions have an impact. This was demonstrated by the PROPPR trial, a multi-institutional, randomized, twogroup, phase III trial comparing a massive transfusion ratio of 1:1:1 packed red blood cells, plasma, and platelets vs a transfusion ratio of 1:1:2 on the outcome of 24-hour and 30-day mortality. 16 The study had a 95% power to detect a difference in mortality of greater than 10% at 24 hours and 92% power to detect a difference in mortality of 12% at 30 days. The 24-hour mortality in the 1:1:1 group was assumed to be 11% and the 30-day mortality was assumed to be 23%. These calculations were based on extensive retrospective data and the prospective observational study, PROMMTT. This phenomenon of the observed difference being lower than the expected difference has been termed delta inflation and multiple theories have been proposed to explain its occurrence. They include investigators choosing a difference based on sample size rather than sample size based on difference, overly optimistic assumptions of treatment efficacy, publication bias of pilot trials with those having lower treatment effects not being published and general improvements in medical care after the power calculation has been performed. [19] [20] [21] Finally, the performance of the study can result in increased medical attention to the patient population and adherence to standards of care. Ultimately for PROPPR to show a statistical difference for the primary outcome, 2,968 patients would have been required to detect the observed difference of 4.2% in the 24-hour group compared to the 680 that were enrolled. Preventing negative and inconclusive clinical trials secondary to under powering of clinical trials is one of the greatest barriers to good clinical research in trauma that must be overcome. Some authors have suggested a buffer to account for delta inflation that could be built into power calculations in the same way that drop outs and lost to follow-up are currently incorporated. 18 Others have suggested since few therapies in critically ill patients have been shown to reduce mortality alternative end points should be used.
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End points other than mortality
When exception from informed consent is utilized in a clinical trial "the research holds out the prospect of direct benefit to the individual." This direct benefit has generally been interpreted as a reduction in 30-day all-cause mortality. Decreased 30-day all-cause mortality is useful for identifying interventions that decrease late mortality in homogenous groups, however it may fail to detect interventions that decrease early mortality from hemorrhage, or result in better neurologic outcomes or improved functional status, all of which would be a "direct benefit to the individual." 23 When a decrease in 30-day all-cause mortality is the standard for granting exception from informed consent, larger studies are required to find early treatments that have an impact on late mortality. The PROPPR study demonstrated how using 30-day all-cause mortality as the primary end point resulted in a failure to show a significant difference between treatment arms. In PROPPR, 86 patients died of hemorrhagic shock between both treatment arms, and of those 86 patients 72 (84%) died in the first 6 hours, contrasting this to TBI which had 62 deaths in the first 30 days, of which 10 (16%) died in the first 6 hours. 24 The majority of deaths from hemorrhage occurred in the first 6 hours while the majority of deaths from TBI occurred later. In a trial that is evaluating resuscitation and hemorrhage control, an alternative earlier cause-specific mortality endpoint may be more appropriate and when evaluating TBI a 1-year functional outcome could be the best indicator of success. Both of these outcomes could measure a "direct benefit to the individual." For new clinical endpoints to be established they must be generally accepted by clinicians and accepted by regulatory bodies. To gain acceptance, endpoints "should be easy to measure, reproducible, valid, clinically meaningful, and resistant to bias." 25 Proposed alternative's to 30-day mortality are ventilator-free days, ICU-free days, multiple-organ-failure free days, 24-hour mortality, 6-hour mortality, time to hemostasis, and functional outcomes scoring. 9, 23, 26 If some of these can be agreed upon by clinicians and accepted by regulatory bodies as alternatives to 30-day all-cause mortality, it would allow for smaller trials that target specific patient groups in the heterogeneous trauma population and help to make trial size and design more manageable.
Variability in practice
After identifying appropriate inclusion and exclusion criteria, effort must be made to reduce the variability in practice between institutions and providers. Differences in emergency, surgical, and critical care can result in different outcomes for similarly injured patients treated at different institutions. It has been consistently shown there is a difference in hospital mortality between similarly designated trauma centers even when accounting for injury severity score, patient characteristics, transfer status, mechanism of injury, and initial vital signs. 27, 28 This difference in mortality has been suggested to exist secondary to differences in ICU protocols, timeliness of surgery, annual patient volume, and emergency department resuscitations. 29 When performing multi-center studies, effort should be made to keep intercenter variability to a minimum allowing comprehensive evaluation of the intervention being investigated. Variability between institutions can be reduced by carefully selecting study sites and investigators, continuously monitoring the progress of the trial, emphasizing accurate data collection and analysis, providing trial specific education, and training and retraining continuously. 9 Creating a multi-center trial that minimizes variability between institutions requires careful planning, well developed protocols, and repeat training. These same principles should be employed in single-center studies in order to reduce variability between providers.
Single IRB
On January 25, 2018 the National Institutes of Health (NIH) issued a final policy requiring the use of a single IRB for multicenter NIH-funded clinical trials. The purpose of this mandate was to streamline the IRB review process, remove hurdles to the initiation of multicenter trials, and reduce unnecessary administrative burdens and systemic inefficiencies, while maintaining appropriate human subject protections. 30 Identified barriers to a single IRB included apprehension about regulatory and legal liability, identifying and addressing issues which may only be identified in the local context, institutional lack of understanding of the single IRB process, and possible loss of income from industry fees for IRB review. 31, 32 As single IRB review is implemented, solutions to these barriers will be identified and new barriers will be arise. When solutions are found, they need to be shared to permit widespread implementation of the single IRB process.
SURGEON BARRIERS Equipoise
Equipoise describes the clinical situation of genuine uncertainty between treatment options which are believed to be equally efficacious. 33 When a disease has two valid treatment options accepted by the surgical community, individual surgeons often have a strong preference for one option. The preference is often based on personal experience or a surgeon's training. This bias is a lack of personal equipoise and can discourage some surgeons from participating in clinical trials for fear of relinquishing control to the process of randomization. 34 Surgeons who participate in trials have various levels of equipoise toward the question the trials is attempting to address. Rooshena et al. 35 recorded appointments of physicians who were recruiting patients to six randomized controlled trials in the United Kingdom and found clinical equipoise to be compromised in 46% of recruitment interviews. Three common ways of compromising equipoise were found. First, physicians offered treatment recommendations when the patient was unsure; second, unbalanced descriptions of trial treatments were given; and finally, physicians disclosed their personal treatment choice. These violations were more likely to occur in physicians who had indicated prior to the interviews that they had less balanced views of the treatment options in the trial. A significant challenge for surgeons who participate in clinical research is separating their personal lack of equipoise to prevent influence on patients, other staff, and the outcome of the study.
Lack of time
As reimbursement for clinical activities has declined there has been a greater focus on clinical activity and away from research. Surgeons are under pressure to treat as many patients as efficiently and effectively as possible in order to maximize revenue. During this same time period the 80-hour work week has reduced the resident workforce necessitating increased faculty clinical responsibility. This leaves little time and energy for clinical research. 36 
OTHER BARRIERS Difficulty in follow-up
When clinical trials have a high lost-to-follow-up rate their power is reduced and the conclusions can become biased.
Researchers have usually considered a 20% lost-to-followup rate to be the maximum before significant bias starts to be introduced. This was demonstrated by Zelle et al. 37 by simulating different rates of lost-to-follow-up in 50 orthopedic trials that found a lost-to-follow-up rate of 20% resulted in a change from significant to nonsignificant differences in over 25% of the trials. The groups at highest risk of being lost to follow up are males, ethnic minorities, those who suffer from substance abuse, and those who have a lower socioeconomic status. 38, 39 These are the same groups that are at the greatest risk of being involved in trauma. 40 This higher rate of dropout must be accounted for when designing and powering trials or the study may not be adequately powered. Prevention strategies to reduce the number of patients lost to follow up that have been shown to be effective are obtaining alternative contact information, making repeated contacts, searching death registries, having multiple follow-up appointments, and having the physician call the patient directly for an appointment. 41 Those affected by trauma are among the most likely to be lost to follow-up and every effort must be made to decrease the number of patients lost to follow-up in order to prevent bias in data.
Complex and costly infrastructure
The uncertainty of when traumatic injury will occur introduces challenges not seen in other disciplines. Severe injury and its time of occurrence are unpredictable events. Clinicians who are present when the patient arrives cannot simultaneously provide clinical care and enroll patients in research studies. 42 The infrastructure required to recruit patients is greater than that of elective patients who present to a specific clinic. It requires an electronic medical record that can identify potential subjects, the presence of trained research assistants 24 hours a day, 7 days a week that can rapidly perform the study tasks while not interfering with patient care. This adds a level of complexity and cost to each trial that is not seen when patients are recruited in clinic on weekdays during business hours. This additional cost and need for 24/7 research assistant coverage can discourage surgeons and trauma centers from developing their own trials and participating in multicenter trials. If it were possible to provide the necessary infrastructure to all trauma centers, then enrollment in multi-institutional studies may be quicker, more generalizable, and perhaps encourage more surgeons and centers to participate in research.
Transport and prehospital care
Time to definitive care in trauma improves survival. Most emergency medical services (EMS) emphasize rapid transport of trauma patients to definitive care. Even with this emphasis there is significant variation in pre-hospital protocols and guidelines. The treatment patients receive in the field influences their overall outcome. 43, 44 If prehospital treatment can change individual outcomes, it can influence the outcome of even the best-designed multi-institutional study. Confounders may be introduced simply by differences in EMS prehospital protocols. Identifying differences in local EMS guidelines and prehospital care is complex and adds another level of difficulty to trauma research. Transport of patients to definitive care from rural locations results in longer transport times to definitive care. 45 Increased transport times can create a survivor bias as patients with rapidly exsanguinating trauma will not survive and those with sustained bleeding or bleeding that is contained with hypotension will arrive alive. Additionally, patients transported from long distances may arrive hypothermic, acidotic, and coagulopathic compared to someone with the same injury and local rapid transport. Accounting for differences in prehospital care introduces challenges to trauma trials and should be accounted for when designing a trial.
Barriers specific to testing cellular therapy and novel product clinical trials in trauma
In addition to the multiple challenges arising in trial design, logistics, patient enrollment, cost, and consent, there are challenges that arise inherent to the testing of novel therapies, specifically cellular therapies (CT), in trauma. 46 Typically in the United States, to gain regulatory approval to test CT in patients, a body of pre-clinical work is required to demonstrate efficacy, safety, dose, and therapeutic windows that optimize outcomes. 47 There are challenges in designing pre-clinical animal models of traumatic injury to accurately represent the clinical scenario and of the heterogeneous nature of disease in a trauma patient. Hence, much of the enabling work conducted in animals for the purposes of efficacy, safety, dose finding, and mechanisms of action, may not be fully translatable to trauma patients. Most animal models are relatively standardized for reproducibility and represent only one scenario and type of injury. Representation of the heterogeneity of patients, for example, suffering from TBI in a mouse model is prohibitive from the standpoint of reproducibility and the numbers of animals that would be required to power the pre-clinical studies. In addition to this challenge at the pre-clinical level, identifying the target cohort of trauma patients who would most likely benefit from cellular therapies based upon the cell type of interest and its mechanisms of action is critical to executing successful clinical trials. The patient cohort, cell type, method of delivery, timing of delivery, dose, and logistics of administration need to be matched closely to the application and desired outcome. For example mesenchymal stem cells (MSCs), a cell type that has been investigated extensively for its immunomodulatory and vascular stabilizing effects, [48] [49] [50] is well suited to support the recovery of trauma patients from inflammatory causes such as infection and organ failure, which occur mostly after 3 days post injury. 17 Based on defined mechanisms of action of MSCs, and pre-clinical studies, it is still unknown whether the clinical MSCs should be administered as a preventative treatment early after trauma or as a treatment after the diagnosis of a condition such as ARDS. There are trials currently underway in trauma patients that will likely answer these unknown questions. This lack of success of interventional therapeutics in trauma, for example TBI trials, is compounded by the heterogeneity of the disease with multiple therapeutic targets and the need for identification of modifiable outcome measures. 51 Another critical area of development is a sufficient and reliable source of production of clinical grade cells for trials and in the future for commercial applications after FDA approval. 47, 52 There is currently no cellular therapy that is FDA (Food and Drug Administration)-approved for commercial production and clinical use in trauma or critical care medicine in the U.S. There is currently no roadmap of methods to optimize and support large-scale cell expansion, and processing of cell products is still in development. Current efforts to produce cells for trials is largely being conducted by academic centers and industry. The success of the trial and interpretability of the trial results is highly dependent on the quality of the cell product being tested.
CONCLUSION
Challenges and barriers to performing high-quality clinical research in the field of trauma are found at nearly every level. Challenges involve patients, providers, institutions, regulatory agencies, and the specific therapeutic intervention being tested. Overcoming these challenges and breaking down barriers that interfere with performing highquality clinical research is critical to improving outcomes of patients affected by traumatic injury and creating evidencebased guidelines. Recognizing and addressing these issues will allow research questions to be answered safely, accurately, and efficiently. High-quality research of traumatic injuries is essential to improving diagnostic accuracy, decreasing costs, decreasing morbidity, and improving mortality of those affected by injury.
